IP Library Granted Patent US 11,046,936
Granted Patent B2
US 11,046,936 · App. 16/319,537 · Granted Jun 29, 2021

Engineered imine reductases and methods for the reductive amination of ketone and amine compounds

Inventors: Margie Tabuga Borra-Garske (Palo Alto, CA); Oscar Alvizo (Fremont, CA); Melissa Ann Mayo (Foster City, CA); Stephan Jenne (Foster City, CA); Auric Anthony Sowell-Kantz (Fairfax, CA); Carmela Molinaro (Colonia, NJ)
Assignee: Codexis, Inc.
C12N9/0028C12N9/0036C12Y105/01C12Y106/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,046,936
App. No.
16/319,537
Granted
Jun 29, 2021
Kind
B2
Abstract

The present application provides engineered polypeptides having imine or oxime reductase activity, polynucleotides encoding the engineered polypeptides, host cells capable of expressing the engineered polypeptides, and methods of using these engineered polypeptides with a range of ketone amine substrate compounds to prepare secondary and tertiary amine product compounds.

Claims (6)

1. An engineered polypeptide comprising an amino acid sequence with at least 80% sequence identity to a reference sequence of SEQ ID NO: 14, and wherein said engineered polypeptide has imine reductase activity.

2. The engineered polypeptide of claim 1 , wherein said polypeptide further comprises at least one substitution selected from 57T/211L, 87S/175G, 103H/212C, 122E, 123G, 124A/178I, 124G, 132H/R, 134R, 171W, 173H/I, 175G/H, 176S, 178I/242Y, 178M, 211L/W, 212C/G/V, 213P/R/T/V, 214M, 215L/M, 217I/L, 234L, and 235K, wherein said positions are numbered with reference to SEQ ID NO:2.

3. The engineered polypeptide of claim 1 , wherein said polypeptide further comprises at least one substitution selected from A57T/I211L, P87S/M175G, R103H/E212C, L122E, T123G, I124A/V178I, I124G, E132H/R, T134R, Y171W, A173H/I, M175G/H, L176S, V178I/A242Y, V178M, I211L/W, E212C/G/V, A213P/R/T/V, V214M, T215L/M, W217I/L, D234L, and A235K, wherein said positions are numbered with reference to SEQ ID NO:2.

4. The engineered polypeptide of claim 1 , wherein said polypeptide comprises an amino acid sequence with at least 80% sequence identity to any even-numbered sequence set forth in SEQ ID NO:4 to SEQ ID NO:74.

5. A method of producing an engineered imine or oxime reductase polypeptide, comprising the steps of culturing a host cell, under conditions such that an engineered polynucleotide is expressed and said engineered polypeptide of claim 1 is produced.

6. The method of claim 5 , further comprising the step of recovering said engineered polypeptide.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (2)
Provisional Application 62380165 · Aug 26, 2016
Related Publication 20200208123A1 · Jul 2, 2020